Dup ! coto! the same as one submitted on

1

'5

ij

		Substitute for f	form 1449A/PTO	PE	Comple	te if Knov		
INF	ORMA	TION D	ISCLOSUR	E '4	Application Number	10/743,6		
ST			APPLICAN'	H-	Filing Date		er 22, 2003	
	(Use seve	eral sheets	if necessary AR 2	6 2004	First Name Inventor	Paul Spu	йт 	
Sheet 1		of 2	· I	Á	Attorney Docket Number	21436	US	
					NT DOCUMENTS			
	G:.	U.S	. Patent Docum	ient	Name of Patentee or Appl	ionet of	Date of Publication	n of
Examiner Initials'	Cite No.'			Kind Code ²	Cited Document	icant or	Cited documer	nt
	1.00	Number		(if known)			MM-DD-YYYY	
les	A1	5,099,	021		Worther et al		03/24/1992	
	A2	3,725,	428		Janiak, S.		<i>8</i> 4/03/1973	
	A3	4,028,	374		Pelosi, Jr. et al.		06/07/1977	
145	A4	6,521,	754		Alanine, et al.		02/18/2003	
					TENT DOCUMENTS			1
F	Cite	Foreign	Patent Docume	ent	Name of Patentee of	۱r	Date of Publication of	T
Examiner Initials'	No.	Office ³	Number*	Kind Code ³	Applicant of Cited Doc	ument	Cited Document	
				(if known)	/		MM-DD-YYYY	
br	B1 ·	WO 0	1/97786		F.Hoffmann-La Roc		12/27/2001	<u> </u>
- V J	B2 ·	EP 0 2	.82 ₉₇₁		Warner Lambert Co.		09/21/1988	
1	B3 '	EP 0 5	29 600		Hoechst Aktiengesel	lschaft	03/03/1993	
	B4 1	EP 0 4	27 963		Wørther et al		05/22/1991	
	B5 ⁴	EP 0 2	95 656		Abe, S. et al		12/21/1988	
	B6 '	DE 19	53149		Ciba AG	.=.	05/06/1970	
	B7	WO 0	0/18767		He, X. et al		04/06/2000	
	B8 1	GB 1 3	345 552A		Societe Nationale De	3	01/30/1974	
					Petroles D'Aquitaine	e		
	B9 1	FR 2 7	753 970 a		Synethelabo		04/03/1998	
	B10	EP 019	99400A /		Jansen Pharmaceutic	als	10/29/1986	
	B11	GB1 5	38 822A		Boehringr Mannhein	n	01/24/1979	
	B12 ·	WO 0	0/278/19A		Novartis AG		05/18/2000	
			04/440	-,	Pfizer Inc.		12/27/1990	
	B14 '		04 657		Otsuka Pharma Co.		07/06/1994	
	B15'	EP 0/3	43 893		Pfizer Inc.		11/29/1989	
			9/24035		Squibb Bristol Myer	S	05/10/1999	
1		/	1//19360a2		Can-Fite Technologi	es	09/08/2000	
De			9/37630		Versicor Inc.		01/22/1990	
Examiner			nsidered	۸ ،		l		
Signature		1/2	<u> </u>	<u>معمدد (</u>	ce with MPEP 609. Draw line through citation		l	duda aaa

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.

Dup 15 ate

,	Sut	stitute for form 1449APTO	Compl	ete if Known	
I	NFORMAT	YON DISCLOSURE	Application Number	10/743,613	
S	TATEMEN	T BY APPLICANT	Filing Date	December 22, 2003	
	(Use severa	d sheets if necessary)	First Name Inventor	Paul Spurr	
Sheet	2	Of 2	Attorney Docket Number	21436 US	

NON PATENT LITERATURE DOCUMENT	NON PA	TENT I	LITERATURE	DOCUMENTS
--------------------------------	--------	--------	------------	-----------

		NON PATENT LITERATURE DOCUMENTS
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
Initials'	No.1	item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue
		number(s), publisher, city and/or country where published
1/2	C1 -	Forlani, L. et al., J. Heterocyclic. Chem. Vol. 37, 2000 pgs. 63-69
	C2 '	McDonald, F. et al., Synthesis 2000, No. 7, pgs. 970-974/
	C3 ′	Abstract corresponding to EP 0 529 600 (Document B3)
	C4 ·	Colotta, V. et al., Arch. Pharm. Med. Chem., 332 (1999) pgs. 39-41
	C5 °	Baraldi, P. G. et al., J. Med. Chem., 39 (1996) pgs. 1164-1171
	C6 4	Li, A. H. et al., J. Med. Chem., 42 (1999) pgs. 706-721
	C7 ·	Kim, Y. C. et al., J. Med. Chem., 41 (1998) pgs. 2835-2845
	C8 '	Li, A. H. et al., J. Med. Chem., 41 (1998) pgs. 3186-3201
	C ₀ ,	Baraldi, P. G. et al., J. Med. Chem., 41 (1998) pgs. 2126-2133
	C10	Poulsen, S. A. et al., Bioorganic & Medicinal Chemistry, 6 (1998)
		pgs. 619-641
	C11.	Müller, C. E. et al., Bioorganic & Medicinal Chemistry, 6 (1998)
		pgs. 707-719
	C12/	Patent Abstracts of Japan, Vol. 1999, No. 10, JP 11 130761a
	C13	Pandeya, Surendra N. et al., Indian Drugs (1985), 23(3), 146-51
		XP0080000299
	C14	Daidone, G. et al., Vol. 44, No. 5 (1989), pgs. 465-473,
	:	XP001053114
	C15.	The Merck Index 12 th Ed. (1996) p. 506
j	C16°	Abstract corresponding to FR 2 753 970 (Document B9)
B	C1/·	Abstract corresponding to WO 00/27819 (Document B12)
Examiner	4,	Sales DATE CONSIDERED 03/14/66
Signature		CONSIDERED 03/14/66

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.

140357

Substitute for form 1449A/TO HAY 2 4 Complete if Known Application Number 10/743,613 INFORMATION DISCLOSURE STATEMENT BY APPLICARY December 22, 2003 Filing Date First Name Inventor Paul Spurr (Use several sheets if necessary) 1614 lors Art Unit: Attorney Docket Number 21436 US of 2 Sheet **U.S. PATENT DOCUMENTS** U.S. Patent Document Date of Publication of Name of Patentee or Applicant of Examiner Cite Kind Code Cited Document Cited document Initials' No.' Number (if known) MM-DD-YYYY 03/24/1992 A1 5,099,021 Worther et al 04/03/1973 Janiak, S. A2 3,725,428 Pelosi, Jr. et al. 06/07/1977 4,028,374 **A3** 6,521,754 Alanine, et al. 02/18/2003 A4 FOREIGN PATENT DOCUMENTS Date of T Foreign Patent Document Name of Patentee or Publication of Examiner Cite Kind Code³ Office³ Number Cited Document Initials' No. Applicant of Cited Document (if known) MM-DD-YYYY WO 01/97786 F.Hoffmann-La Roche AG 12/27/2001 11/5 **B1** Warner Lambert Co. 09/21/1988 EP 0 282 971 **B2** Hoechst Aktiengesellschaft 03/03/1993 EP 0 529 600 **B3** 05/22/1991 **B4** EP 0 427 963 Worther et al Abe, S. et al 12/21/1988 **B5** EP 0 295 656 Ciba AG 05/06/1970 DE 1953149 **B6** He, X. et al 04/06/2000 WO 00/18767 **B7** Societe Nationale De 01/30/1974 GB 1 345 552A **B8** Petroles D'Aquitaine 04/03/1998 Synethelabo FR 2 753 970 a B9 Jansen Pharmaceuticals 10/29/1986 EP 0199400A **B10** Boehringr Mannheim 01/24/1979 GB1 538 822A **B11** 05/18/2000 Novartis AG WO 00/27819A **B12** EP 0 404 440 Pfizer Inc. 12/27/1990 B13 Otsuka Pharma Co. 07/06/1994 **B14** EP 0 604 657 Pfizer Inc. 11/29/1989 B15 EP 0 343 893 Squibb Bristol Myers 05/10/1999 **B16** WO 99/24035

Signature | Signat

Versicor Inc.

WO 01//19360a2

WO 99/37630 Date Considered

B17

B18

Examiner

Can-Fite Technologies

Sales

09/08/2000

01/22/1990

torm with next communication to approxim.

Unique citation designation number. See attached Kinds of U.S. Patent Documents, Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known		
				RMATION DISCLOSURE Application Number		
				Filing Date	December 22, 2003	
				First Name Inventor	Paul Spurr	
				Art Unit:	1614- 1626	
Sheet	2	of	2	Attorney Docket Number	21436 US	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue	T ²
Bs	C1	number(s), publisher, city and/or country where published Forlani, L. et al., J. Heterocyclic. Chem. Vol. 37, 2000 pgs. 63-69	
1	C2	McDonald, F. et al., Synthesis 2000, No. 7, pgs. 970-974	
	C3	Abstract corresponding to EP 0 529 600 (Document B3) @3 1993	
	C4	Colotta, V. et al., Arch. Pharm. Med. Chem., 332 (1999) pgs. 39-41	
	C5	Baraldi, P. G. et al., J. Med. Chem., 39 (1996) pgs. 1164-1171	
	C6	Li, A. H. et al., J. Med. Chem., 42 (1999) pgs. 706-721	
	C7	Kim, Y. C. et al., J. Med. Chem., 41 (1998) pgs. 2835-2845	
	C8	Li, A. H. et al., J. Med. Chem., 41 (1998) pgs. 3186-3201	
	C9	Baraldi, P. G. et al., J. Med. Chem., 41 (1998) pgs. 2126-2133	
	C10	Poulsen, S. A. et al., Bioorganic & Medicinal Chemistry, 6 (1998) pgs. 619-641	
	C11	Müller, C. E. et al., Bioorganic & Medicinal Chemistry, 6 (1998) pgs. 707-719	
	C12	Patent Abstracts of Japan, Vol. 1999, No. 10, JP 11 130761a	
	C13	Pandeya, Surendra N. et al., <i>Indian Drugs</i> (1985), 23(3), 146-51 XP0080000199	
	C14	Daidone, G. et al., Vol. 44, No. 5 (1989), pgs. 465-473, XP001053114	
	C15	The Merck Index 12 th Ed. (1996) p. 506	
	C16	Abstract corresponding to FR 2 753 970 (Document B9) 1998	
15	C17		
Examiner Signature	12	Ose DATE CONSIDERED 07/14/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

140357

Complete if Known **DISCLOSURE** Application Number 10/743,613 STATEMENT BY APPLICANT Filing Date December 22, 2003 First Name Inventor Paul Spurr 16/4 1620 (Use several sheets if necessary) Group Art Unit Seed Examiner Name Attorney Docket Number of 1 21436 US Sheet

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	T ²
nitials'	No.1	of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-	
		issue number(s), publisher, city and/or country where published	 -
0-0	C18	CARLA BOGA et al, Journal of the Chemical Society, Perkin	
Kis		Transactions 1, XP002296456, pgs. 1363-1368 (1999)	
			<u> </u>
		·	
			<u> </u>
	- 		
			ļ
			ļ
			<u> </u>
	Ti T		
	 		
	-		
			-
			-
_			
			<u> </u>
xaminer ignature	k o-	DATE CONSIDERED 03/14/06	

Signature | CONSIDERED | 0 3 | 14 06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

146808